JP2002530341A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002530341A5 JP2002530341A5 JP2000583533A JP2000583533A JP2002530341A5 JP 2002530341 A5 JP2002530341 A5 JP 2002530341A5 JP 2000583533 A JP2000583533 A JP 2000583533A JP 2000583533 A JP2000583533 A JP 2000583533A JP 2002530341 A5 JP2002530341 A5 JP 2002530341A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- jig
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- FHPIXVHJEIZKJW-UHFFFAOYSA-N 4'-N-desmethylolanzapine Chemical compound S1C(C)=CC2=C1NC1=CC=CC=C1N=C2N1CCNCC1 FHPIXVHJEIZKJW-UHFFFAOYSA-N 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 12
- 208000019901 Anxiety disease Diseases 0.000 description 6
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960002464 fluoxetine Drugs 0.000 description 3
- 229960004038 fluvoxamine Drugs 0.000 description 3
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 3
- 229960001800 nefazodone Drugs 0.000 description 3
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 3
- 229960002296 paroxetine Drugs 0.000 description 3
- 229960004688 venlafaxine Drugs 0.000 description 3
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- -1 methyl olanzapine Chemical compound 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010017543 Fungal skin infection Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000016686 tic disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10958498P | 1998-11-23 | 1998-11-23 | |
| US60/109,584 | 1998-11-23 | ||
| PCT/US1999/027647 WO2000030650A1 (en) | 1998-11-23 | 1999-11-22 | Desmethylolanzapine compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002530341A JP2002530341A (ja) | 2002-09-17 |
| JP2002530341A5 true JP2002530341A5 (https=) | 2007-03-01 |
Family
ID=22328453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000583533A Withdrawn JP2002530341A (ja) | 1998-11-23 | 1999-11-22 | デスメチルオランザピン組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6348455B1 (https=) |
| EP (1) | EP1133300B1 (https=) |
| JP (1) | JP2002530341A (https=) |
| AT (1) | ATE286398T1 (https=) |
| AU (1) | AU757973B2 (https=) |
| CA (1) | CA2351718A1 (https=) |
| DE (1) | DE69923081T2 (https=) |
| ES (1) | ES2237188T3 (https=) |
| PT (1) | PT1133300E (https=) |
| WO (1) | WO2000030650A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200402289A (en) * | 2002-05-17 | 2004-02-16 | Wyeth Corp | Methods of treating gastrointestinary and genitourinary pain disorders |
| PL199016B1 (pl) | 2002-06-20 | 2008-08-29 | Adamed Sp Z Oo | Sposób wytwarzania olanzapiny |
| US6831077B2 (en) * | 2002-07-25 | 2004-12-14 | Comprehensive Neuroscience, Inc. | Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation |
| CA2529857A1 (en) * | 2002-07-30 | 2004-02-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| KR100842694B1 (ko) | 2002-12-27 | 2008-07-01 | 오쓰까 세이야꾸 가부시키가이샤 | 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제 |
| AR042806A1 (es) * | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
| US7763660B2 (en) * | 2003-02-05 | 2010-07-27 | The University Of Vermont And State Agricultural College | Inhibitors of Candida albicans |
| PL198589B1 (pl) | 2004-11-22 | 2008-06-30 | Adamed Sp Z Oo | Sposób wytwarzania N-demetyloolanzapiny |
| WO2006081327A2 (en) * | 2005-01-25 | 2006-08-03 | University Of Vermont And State Agricultural College | Small molecules that reduce fungal growth |
| US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
| JP2010518023A (ja) * | 2007-02-01 | 2010-05-27 | アラン アイ． グリーン | ドーパミンＤ２受容体遮断剤とノルエピネフリン再取り込み阻害剤およびノルエピネフリンα２受容体遮断剤との組み合わせ |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4115568A (en) | 1974-11-26 | 1978-09-19 | Lilly Industries Limited | Thieno[3,2-b]-[1,5]benzodiazepines |
| US4590213A (en) * | 1983-04-08 | 1986-05-20 | Eli Lilly And Company | Anti-anxiety method |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5627178A (en) | 1991-04-23 | 1997-05-06 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5605897A (en) * | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
| US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
| JPH11512705A (ja) | 1995-09-29 | 1999-11-02 | イーライ・リリー・アンド・カンパニー | チック症を処置する方法 |
| CA2240836A1 (en) | 1995-12-21 | 1997-07-03 | Pierre Van Tran | Method for treating dermatitis |
| HUP9903684A3 (en) | 1995-12-22 | 2001-12-28 | Lilly Co Eli | Use of olanzapine for the preparation of pharmaceutical compositions treating depression |
| HUP9903679A3 (en) | 1996-03-11 | 2001-10-29 | Lilly Co Eli | Use of olanzapine for the preparation of pharmaceutical compositions treating bipolar disorder |
| KR19990087714A (ko) * | 1996-03-11 | 1999-12-27 | 피터 지. 스트링거 | 물질 남용의 치료 방법 |
| UA57727C2 (uk) * | 1996-03-11 | 2003-07-15 | Елі Ліллі Енд Компані | Спосіб лікування надмірної агресивності |
| TR199801798T2 (xx) * | 1996-03-11 | 1998-12-21 | Eli Lilly And Company | Otizm tedavisi. |
| GB9615767D0 (en) | 1996-07-26 | 1996-09-04 | Smithkline Beecham Plc | Novel treatment |
-
1999
- 1999-11-22 CA CA002351718A patent/CA2351718A1/en not_active Abandoned
- 1999-11-22 EP EP99960547A patent/EP1133300B1/en not_active Expired - Lifetime
- 1999-11-22 ES ES99960547T patent/ES2237188T3/es not_active Expired - Lifetime
- 1999-11-22 JP JP2000583533A patent/JP2002530341A/ja not_active Withdrawn
- 1999-11-22 DE DE69923081T patent/DE69923081T2/de not_active Expired - Fee Related
- 1999-11-22 PT PT99960547T patent/PT1133300E/pt unknown
- 1999-11-22 US US09/444,590 patent/US6348455B1/en not_active Expired - Fee Related
- 1999-11-22 WO PCT/US1999/027647 patent/WO2000030650A1/en not_active Ceased
- 1999-11-22 AU AU17416/00A patent/AU757973B2/en not_active Ceased
- 1999-11-22 AT AT99960547T patent/ATE286398T1/de not_active IP Right Cessation
-
2001
- 2001-12-19 US US10/026,303 patent/US6468997B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR980000447A (ko) | 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물 | |
| RU97110083A (ru) | Комбинация, фармацевтическая композиция, способ лечения, использование и упаковка | |
| JPH1067663A5 (https=) | ||
| ES2351190T3 (es) | Utilización de rotigotina para el tratamiento de depresiones. | |
| CN1832734B (zh) | 用于治疗抑郁症的取代的2-氨基1,2,3,4-四氢化萘 | |
| JP2017509686A5 (https=) | ||
| JP2002530341A5 (https=) | ||
| AR080849A2 (es) | Uso de una composicion farmaceutica de un compuesto de carboestirilo | |
| JP2004519469A5 (https=) | ||
| JP2005515966A5 (https=) | ||
| JP2009526754A5 (https=) | ||
| JP2009280605A (ja) | （＋）−１−（３，４−ジクロロフェニル）−３−アザビシクロ［３．１．０］ヘキサン、その組成物および使用 | |
| JP2008044951A5 (https=) | ||
| BRPI0415683A (pt) | inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central | |
| JP2013544850A5 (https=) | ||
| RU2005122008A (ru) | Препараты с контролируемым высвобождением, содержащие трамадол и топирамат | |
| JP2009538276A5 (https=) | ||
| JP2002516282A5 (https=) | ||
| JP2007510736A5 (https=) | ||
| JP2002524415A5 (https=) | ||
| JP2005500298A5 (https=) | ||
| JP2003504332A5 (https=) | ||
| JP2007513052A5 (https=) | ||
| RU2007120690A (ru) | Комбинации антагонистов никотинового ацетилхолинового альфа-7-рецептора | |
| RU2009120115A (ru) | Фармацевтическая композиция, обладающая антипсихотической, антидепрессантной или противоэпилептической активностью, со сниженным побочным эффектом |